Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
4.260
-0.320 (-6.99%)
Mar 31, 2025, 4:00 PM EDT - Market closed

Protara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2017
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2017
Selling, General & Admin
17.4518.6220.7426.422.46
Upgrade
Research & Development
31.724.9916.8121.0911.98
Upgrade
Operating Expenses
49.1543.6137.5547.4934.44
Upgrade
Operating Income
-49.15-43.61-37.55-47.49-34.44
Upgrade
Interest Expense
-----0.03
Upgrade
Interest & Investment Income
4.173.191.110.240.5
Upgrade
Other Non Operating Income (Expenses)
0.39----
Upgrade
EBT Excluding Unusual Items
-44.6-40.42-36.44-47.25-33.98
Upgrade
Impairment of Goodwill
---29.52--
Upgrade
Pretax Income
-44.6-40.42-65.95-47.25-33.98
Upgrade
Net Income
-44.6-40.42-65.95-47.25-33.98
Upgrade
Net Income to Common
-44.6-40.42-65.95-47.25-33.98
Upgrade
Shares Outstanding (Basic)
211111117
Upgrade
Shares Outstanding (Diluted)
211111117
Upgrade
Shares Change (YoY)
81.73%0.64%0.24%55.28%180.66%
Upgrade
EPS (Basic)
-2.17-3.57-5.86-4.21-4.70
Upgrade
EPS (Diluted)
-2.17-3.57-5.86-4.21-4.70
Upgrade
Free Cash Flow
-35.87-37.6-26.58-35.1-24.29
Upgrade
Free Cash Flow Per Share
-1.74-3.32-2.36-3.13-3.36
Upgrade
EBITDA
-48.82-43.27-37.3-47.37-34.34
Upgrade
D&A For EBITDA
0.330.340.250.120.1
Upgrade
EBIT
-49.15-43.61-37.55-47.49-34.44
Upgrade
Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q